Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:03:07.193Z.
Calculation as of: 2026-10-06T16:03:07.193Z.
Quote observation: 2026-10-06T16:00:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02887d9f7d553dead588493e3d1cc1cda6164751857f77264c258b40fe63259
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Fulcrum Therapeutics, Inc.
Market Cap
$283.83M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.97M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$280.29M
EV/EBITDA Ratio
N/A
TTM Avg
10.42x
3Y Avg
23.40x
5Y Avg
23.40x
Market Cap
$288.40M
EV/EBITDA Ratio
N/A
TTM Avg
18.83x
3Y Avg
18.83x
5Y Avg
18.83x
Market Cap
$289.63M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$274.62M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$295.12M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $283.83M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $281.97M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | N/A | 10.42x | 23.40x | 23.40x |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.40M | N/A | 18.83x | 18.83x | 18.83x |
| Standard BioTools Inc. (LAB)vs › | $288.98M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $278.55M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.12M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $268.71M | N/A | 10.21x | 10.21x | 10.68x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
